International Journal of Antimicrobial Agents
Volume 35, Issue 5 , Pages 473-477 , May 2010

Predictors of acute kidney injury associated with intravenous colistin treatment

  • Jeong-Ah Kwon

      Affiliations

    • Division of Nephrology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, South Korea
    • ,
  • Jung Eun Lee

      Affiliations

    • Division of Nephrology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, South Korea
    • Corresponding Author InformationCorresponding author. Tel.: +82 2 3410 6549; fax: +82 2 3410 0064.
    • ,
  • Wooseong Huh

      Affiliations

    • Division of Nephrology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, South Korea
    • ,
  • Kyong Ran Peck

      Affiliations

    • Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
    • ,
  • Yoon-Goo Kim

      Affiliations

    • Division of Nephrology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, South Korea
    • ,
  • Dae Joong Kim

      Affiliations

    • Division of Nephrology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, South Korea
    • ,
  • Ha Young Oh

      Affiliations

    • Division of Nephrology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, South Korea

Received 24 September 2009 ,Accepted 1 December 2009.

References 

  1. Waterer GW, Wunderink RG. Increasing threat of Gram-negative bacteria. Crit Care Med. 2001;29:N75–N81
  2. Wareham DW, Bean DC, Khanna P, Hennessy EM, Krahe D, Ely A, et al. Bloodstream infection due to Acinetobacter spp.: epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis. 2008;27:607–612
  3. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis. 2005;40:1333–1341
  4. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents. 2005;25:11–25
  5. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6:589–601
  6. Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents. 2005;26:504–507
  7. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect. 2005;11:115–121
  8. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009;48:1724–1728
  9. Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int. 2008;73:538–546
  10. Ali T, Khan I, Simpson W, Prescott G, Townend J, Smith W, et al. Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol. 2007;18:1292–1298
  11. National Kidney Foundation . K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl. 1):S1–S266
  12. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8:R204–R212
  13. Kallel H, Hergafi L, Bahloul M, Hakim A, Dammak H, Chelly H, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case–control study. Intensive Care Med. 2007;33:1162–1167
  14. Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents. 2009;34:434–438
  15. Lanese DM, Conger JD. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest. 1993;91:2144–2149
  16. Fogarty BJ, Parks RW, Rowlands BJ, Diamond T. Renal dysfunction in obstructive jaundice. Br J Surg. 1995;82:877–884
  17. Betjes MG, Bajema I. The pathology of jaundice-related renal insufficiency: cholemic nephrosis revisited. J Nephrol. 2006;19:229–233
  18. Desai TK, Tsang TK. Aminoglycoside nephrotoxicity in obstructive jaundice. Am J Med. 1988;85:47–50
  19. Oliveira JF, Silva CA, Barbieri CD, Oliveira GM, Zanetta DM, Burdmann EA. Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units. Antimicrob Agents Chemother. 2009;53:2887–2891
  20. Nanji AA, Stewart DJ, Mikhael NZ. Hyperuricemia and hypoalbuminemia predispose to cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol. 1986;17:274–276
  21. Humes HD. Aminoglycoside nephrotoxicity. Kidney Int. 1988;33:900–911
  22. Sawaya BP, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol. 1995;6:154–164
  23. Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Arruda EA, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis. 1999;28:1008–1011
  24. Falagas ME, Kasiakou SK, Kofteridis DP, Roditakis G, Samonis G. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) Gram-negative bacteria. Eur J Clin Microbiol Infect Dis. 2006;25:596–599
  25. Pintado V, San Miguel LG, Grill F, Mejia B, Cobo J, Fortun J, et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant Gram-negative bacteria. J Infect. 2008;56:185–190

PII: S0924-8579(09)00575-5

doi: 10.1016/j.ijantimicag.2009.12.002

International Journal of Antimicrobial Agents
Volume 35, Issue 5 , Pages 473-477 , May 2010

Article Tools

* Image Usage & Resolution